Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 1 · 33.3%Moderate 1 · 33.3%High 0 · 0%

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Sclerotherapy plus compression showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy alone (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 1.84 [0.17, 19.62]
1 study · 96 participants
Low

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy plus compression showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy alone (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.93 [0.41, 2.07]
2 studies · 196 participants
Moderate

Ultrasound‐accelerated thrombolysis vs thrombolysis alone

Adverse events · adults with ALI

It is very uncertain whether ultrasound‐accelerated thrombolysis changes adverse events compared with thrombolysis alone (very low certainty).

1 finding from 1 review

Percutaneous thrombectomy or ultrasound‐accelerated thrombolysis for initial management of acute limb ischaemia 2022 · Cochrane Headline outcomes only
RR 5.69 [0.28, 113.72]
1 study · 60 participants
Very low